Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pectin under stress: Pectin methylesterases at the core of cell wall remodeling, integrity sensing, and signaling in plants.

Plant communications·2026

Same author

Galectin-3 binding protein is upregulated in heart failure with preserved ejection fraction and associated with endothelial nitric oxide synthase deficiency.

GeroScience·2026

Same author

The medium-chain fatty acid octanoate is a beneficial fuel for the failing heart.

American journal of physiology. Heart and circulatory physiology·2026

Same author

The multidimensional signature of oxysterols: Comparative RPLC-HRMS-based profiling of healthy and pancreatic tumour cell lines.

Talanta·2026

Same author

Attitudes, knowledge, practices, and perceived barriers on sustainability actions among Italian anesthesiologists-intensivists: a nationwide survey.

Journal of anesthesia, analgesia and critical care·2026

Same author

From Waste to Defense: Agro-Industrial Byproducts as Sources of Biopesticides and Bioelicitors for Crop Protection.

Journal of agricultural and food chemistry·2026

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart

Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart

Published on: September 28, 2016

Modulating fatty acid oxidation in heart failure.

Vincenzo Lionetti¹, William C Stanley, Fabio A Recchia

¹Gruppo Intini-SMA Laboratory of Experimental Cardiology, Scuola Superiore Sant'Anna, Pisa, Italy.

Cardiovascular Research

|February 4, 2011

Summary

This summary is machine-generated.

Altered heart metabolism in heart failure involves reduced fatty acid oxidation and increased glucose use. Modulating fatty acid oxidation shows promise for metabolic therapy, though further research is needed.

More Related Videos

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Related Experiment Videos

Last Updated: Jun 4, 2026

Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart

Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart

Published on: September 28, 2016

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Area of Science:

Cardiology
Biochemistry
Pharmacology

Background:

Advanced heart failure alters myocardial energy substrate metabolism.
Key enzymes show down-regulation, leading to reduced fatty acid oxidation and increased glycolysis.
The metabolic shift's role as adaptive or maladaptive remains unclear.

Purpose of the Study:

To review pharmacological agents targeting fatty acid (FA) oxidation for heart failure metabolic therapy.
To evaluate the therapeutic potential of modulating myocardial substrate utilization.

Main Methods:

Review of indirect and direct modulators of fatty acid oxidation.
Analysis of evidence from clinical trials on FA metabolism modulators.

Main Results:

Evidence for FA metabolism modulators in heart failure is mixed.
Molecular and biochemical alterations induced by these agents are complex.
Small trials show benefits from perhexiline and trimetazidine.

Conclusions:

Pharmacological modulation of myocardial substrate utilization is a promising therapeutic strategy for heart failure.
Further research is needed to understand the complexities of FA metabolism modulation.
Perhexiline and trimetazidine suggest potential benefits warranting further investigation.